2013 Boehringer Ingelheim AASV Pre-Conference Seminar: Vertical Transmission

Boehringer Ingelheim Featured Presentations

Effects and Costs of Swine Respiratory Diseases

Porcine Respiratory Disease ComplexUnderstanding Porcine Respiratory Disease Complex Dr. Christa Goodell, Technical Manager, Boehringer Ingelheim Vetmedica, Inc., and Dr. Reid Philips, PRRS Senior Technical Manager, Boehringer Ingelheim, provides insight on the impact and costs of porcine respiratory diseases like Porcine Respiratory Disease Complex (PRDC), Porcine Reproductive And Respiratory Syndrome virus (PRRSv), and Influenza A Virus in Swine (IAV-S). Drs. Goodell and Philips outline approaches to diagnosis, treatment, and prevention within swine operations [video].

Boehringer Ingelheim Science In Practice Reception

Science In Practice ReceptionScience In Practice Reception Boehringer Ingelheim remembered Dr. Bob Morrison in their pre-Allen D. Leman Conference Science In Practice Reception. Additionally, Dr. Bob Thompson, PIC, received the the Science in Practice Award [video].

Comparison of Intestinal Lesions

Comparison of intestinal lesions between Enterisol® Ileitis and Porcilis® Ileitis using a Lawsonia intracellularis mucosal homogenate seeder pig challenge modelComparison of intestinal lesions between Enterisol® Ileitis and Porcilis® Ileitis using a Lawsonia intracellularis mucosal homogenate seeder pig challenge model Dr. Jessica Seate, Boehringer Ingelheim Vetmedica, Inc, presents research on a comparison of intestinal lesions between Enterisol® Ileitis and Porcilis® Ileitis using a Lawsonia intracellularis mucosal homogenate seeder pig challenge model. Dr. Seate concludes with a summary that shares that IHC scores and histologic lesions (H&E) were lower for Enterisol® Ileitis group compared to the Porcilis® Ileitis and NVC groups, Enterisol® Ileitis had lowest percentage of PCR positives at necropsy, and IgG Lawsonia ELISA titers are not indicative of protective immunity [video].

Efficacy of Ingelvac PRRS® MLV

Efficacy of Ingelvac PRRS® MLV against a heterologous PRRSV 1-7-4 RFLP challengeEfficacy of Ingelvac PRRS® MLV against a heterologous PRRSV 1-7-4 RFLP challenge Dr. Reid Philips, Boehringer Ingelheim Vetmedica, Inc, shares insights on the efficacy of Ingelvac PRRS® MLV against a heterologous PRRSV 1-7-4 RFLP challenge. Key findings include: Ingelvac PRRS® MLV demonstrated significant protection against a virulent PRRSv ‘174’ challenge: 1) Significant reduction in viremia, 2) Significant reduction in lung lesions, and 3) Significant improvement in Daily Gain. Also, Ingelvac PRRS® MLV continues to demonstrate cross protection against new-emerging field strains [video].

Comparison Of Efficacy Between Two Pcv2 Vaccination Protocols

Comparison of efficacy between two PCV2 vaccination protocols under PCV2d field exposureComparison of efficacy between two PCV2 vaccination protocols under PCV2d field exposure Dr. Eduardo Fano, Boehringer Ingelheim Vetmedica, Inc, shares a research comparison of efficacy between two PCV2 vaccination protocols under PCV2d field exposure. Key finding: No efficacy differences between these 2 vaccination protocols were documented in this study under 1) PCV2d field/natural challenge, and 2) PRRSV Co infection [video].

Welcome!

2013 Boehringer Ingelheim Vertical TransmissionThe 2013 Boehringer Ingelheim Vertical Transmission AASV BI Pre-Conference Seminar, March 1, 2013, San Diego, CA, USA, brought together swine veterinarians from around the US to talk about… sick pigs.

The Boehringer Ingelheim pre-AASV symposium provided in-depth perspective on vertical transmission of disease in addition to timeline considerations, like "If the pig coughs today, when should treatment have started?"

Spend a few minutes reviewing these important presentations, then share your thoughts with your herd health staff.

This event immediately preceded the American Association of Swine Veterinarians' annual conference, also in San Diego.

Ned Arthur
Your SwineCast Host
Ned Arthur's picture
email us or call 1.877.SwineCast (1.877.794.6322).